Supplementary Information

Supplemental Figure legends

Figure S1. qRT-PCR analysis of CASC15 RNA levels in A549 and H1299 cells, which were treated with si-Control or si-CASC15 for 48 hours.

Figure S2. Western blot analysis of SOX4 protein levels in A549 and H1299 cells, which were treated with si-Control or si-SOX4 for 48 hours.

Figure S3. Tumor volume in nude mice injected with A549 and H129 cells with stable knockdown of CASC15, or concurrent overexpression of SOX4.

Figure S4. Representative IHC staining of HIF-1α and ISH staining of CASC15 in A549-shControl and A549-shHIF1A xenograft tissues.

Figure S5. Western blot analysis of SOX4 protein levels in CASC15-overexpressing H1299 cells and control cells.

Figure S6. RNA-IP assay detecting potential interactions between CASC15 RNA and WDR5 protein in A549 and H1299 cells. U1 snRNA, which was reported not binding to WDR5, was used as a negative control.

Table S1. The characteristics of 35 NSCLC patients included in the tissue microarray in our study.

Table S2. Primer sequences for qRT-PCR.

Figure S1




Figure S2




Figure S3




Figure S4




Figure S5




Figure S6




Table S1

Characteristics	Case (n, %)	
Age (years)	Media: 60; Range: 47-74	
< 60	17 (48.6)	
≥ 60	18 (51.4)	
Gender		
Male	20 (57.1)	
Female	15 (42.9)	
Pathologic type		
Adenocarcinoma	19 (54.3)	
Squamous cell carcinoma	11 (31.4)	
Others	5 (14.3)	
Differentiated degree		
Well	8 (22.9)	
Media	15 (42.9)	
Poor	12 (34.3)	
T stage		
1-11	25 (71.4)	
III-IV	10 (28.6)	
Tumor size		
< 3 cm	8 (22.9)	
≥ 3 cm	27 (77.1)	
Lymph nodes metastasis		
No	24 (68.6)	
Yes	11 (31.4)	

Table S2

Primer Sequences for qRT-PCR		
Gene	Strand	Sequences
CASC15	forward	5'-TTAGGGAAAGCCTTCTTTAGGGAT-3'
	reverse	5'-CTCCCAGCCCCTATTCCTTT-3'
HIF1A	forward	5'-TTTTTCAAGCAGTAGGAATTGGA-3'
	reverse	5'-GTGATGTAGCTGCATGATCG-3'
SOX4	forward	5'-CCAAATCTTTTGGGGACTTTT-3'
	reverse	5'-CTGGCCCTCAACTCCTC-3'

CTNNB1	forward	5'-ACAGGGAAGACATCACTGAGCC-3'
	reverse	5'-CAGTGGGATGGTGGGTGTAAGA-3'
18S rRNA	forward	5'-GTAACCCGTTGAACCCCATT-3'
	reverse	5'-CCATCCAATCGGTAGTAGCG-3'
GAPDH	forward	5'-TCGGAGTCAACGGATTTGGT-3'
	reverse	5'-TCGCCCACTTGATTTTGGA-3'